Important Announcement

X

ChemIDplus is moving to PubChem in December 2022.
Please see the NLM Technical Bulletin article for more information.

Skip Navigation
ChemIDplus Lite•Browse•Advanced

Substance Name: Acyclovir [USAN:USP]
RN: 59277-89-3
UNII: X4HES1O11F
InChIKey: MKUXAQIIEYXACX-UHFFFAOYSA-N

Note

  • A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Molecular Formula

  • C8-H11-N5-O3

Molecular Weight

  • 225.2069
 

Classification Codes

Classification Codes

  • Anti-Infective Agents
  • Antiviral
  • Antiviral Agents
  • Drug / Therapeutic Agent
  • Human Data
  • Mutation Data
  • Reproductive Effect

Superlist Classification Code

  • Overall Carcinogenic Evaluation: Group 3
* denotes mobile formatted website

Links to Resources

NLM Resources (File Locators)

Regulatory Agencies (Superlist Locators)

Other Resources (Internet Locators)


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Aciclovir [INN]
  • Acyclovir
  • Acyclovir [USAN:USP]

MeSH Heading

  • Acyclovir

Synonyms

  • 2-Amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6H-purin-6-one
  • 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-
  • 9-((2-Hydroxyethoxy)methyl)guanine
  • Aciclovir
  • Aciclovirum
  • Aciclovirum [INN-Latin]
  • Aciclovirum [Latin]
  • Activir
  • ACV
  • Acycloguanosine
  • Acyclovir
  • BW-248U
  • CCRIS 1953
  • DRG-0008
  • EINECS 261-685-1
  • Hascovir
  • HSDB 6511
  • NSC 645011
  • Sitavig
  • UNII-X4HES1O11F
  • Vipral
  • Virorax
  • W-248-U
  • Wellcome-248U
  • Zovirax

Systematic Names

  • 6H-Purin-6-one, 1,9-dihydro-2-amino-9-((2-hydroxyethoxy)methyl)-
  • 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-
  • Aciclovir
  • Acyclovir

Superlist Name

  • Aciclovir

Mixture Name

  • Xerese

Registry Numbers

CAS Registry Number

  • 59277-89-3

FDA UNII

  • X4HES1O11F

System Generated Number

  • 0059277893

Structure Descriptors

InChI

InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)

InChIKey

MKUXAQIIEYXACX-UHFFFAOYSA-N

Smiles

NC1=Nc2c(ncn2COCCO)C(=O)N1

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
child TDLo oral 3gm/kg/22W-I (3000mg/kg) BLOOD: AGRANULOCYTOSIS

BLOOD: THROMBOCYTOPENIA		 American Journal of Emergency Medicine. Vol. 16, Pg. 396, 1998.
mammal (species unspecified) LD50 intravenous 400mg/kg (400mg/kg)   Pharmacy International. Vol. 5, Pg. 191, 1984.
man TDLo intravenous 134ug/kg/1D-I (0.134mg/kg) BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" Lancet. Vol. 2, Pg. 385, 1985.
man TDLo intravenous 107mg/kg/4D-I (107mg/kg) KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"

BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"		 American Journal of Kidney Diseases. Vol. 22, Pg. 611, 1993.
man TDLo oral 486mg/kg/17D- (486mg/kg) GASTROINTESTINAL: OTHER CHANGES

GASTROINTESTINAL: DECREASED MOTILITY OR CONSTIPATION		 American Journal of Gastroenterology. Vol. 88, Pg. 2110, 1993.
mouse LD50 intraperitoneal 724mg/kg (724mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 25, Pg. 815, 1994.
mouse LD50 intravenous 1118mg/kg (1118mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 16, Pg. 866, 1985.
mouse LD50 oral > 10gm/kg (10000mg/kg)   Nature. Vol. 272, Pg. 583, 1978.
mouse LD50 subcutaneous 1118mg/kg (1118mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 16, Pg. 866, 1985.
rat LD50 intraperitoneal 860mg/kg (860mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 16, Pg. 866, 1985.
rat LD50 intravenous 750mg/kg (750mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 25, Pg. 815, 1994.
rat LD50 oral > 20gm/kg (20000mg/kg)   Drugs in Japan Vol. -, Pg. 7, 1990.
rat LD50 subcutaneous 620mg/kg (620mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 16, Pg. 866, 1985.
women LDLo multiple routes 36mg/kg/2D-I (36mg/kg) BEHAVIORAL: COMA

BRAIN AND COVERINGS: OTHER DEGENERATIVE CHANGES

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES		 American Journal of Kidney Diseases. Vol. 20, Pg. 647, 1992.
women TDLo intravenous 101mg/kg/2D-I (101mg/kg) BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"

BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)		 American Journal of Medicine. Vol. 94, Pg. 212, 1993.
women TDLo oral 12mg/kg/1D-I (12mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ANTIPSYCHOTIC

BRAIN AND COVERINGS: MENINGEAL CHANGES		 Southern Medical Journal. Vol. 87, Pg. 1227, 1994.
women TDLo oral 28mg/kg/2D-I (28mg/kg) LUNGS, THORAX, OR RESPIRATION: SPUTUM

BRAIN AND COVERINGS: CHANGES IN SURFACE EEG

BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"		 Southern Medical Journal. Vol. 87, Pg. 1227, 1994.
women TDLo oral 80mg/kg/4D-I (80mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD		 Annals of Internal Medicine. Vol. 111, Pg. 187, 1989.
women TDLo oral 100mg/kg/5D-I (100mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" British Medical Journal. Vol. 289, Pg. 1424, 1984.

Physical Properties

Physical Property Value Units Temp (deg C) Source
Melting Point 255 deg C   EXP
log P (octanol-water) -1.56E+00 (none)   EXP
Water Solubility 1620 mg/L 22 EXP
Vapor Pressure 7.47E-15 mm Hg 25 EST
Henry's Law Constant 3.18E-22 atm-m3/mole 25 EST
Atmospheric OH Rate Constant 7.94E-11 cm3/molecule-sec 25 EST

Physical property data is provided to ChemIDplus by SRC, Inc.